N-acetylcysteine combined with pulmonary surfactant alleviates neonatal severe fetus seizure syndrome through regulating fetal inflammatory factors and oxygenation

doi:10.12092/j.issn.1009-2501.2020.01.012

Abstract

Abstract: AIM: To analyze the effects of N-acetylcysteine (NAC) combined with alveolar surfactant (PS) on the efficacy and serum inflammatory factors and oxygenation in children with meconium aspiration syndrome (MAS). METHODS: Sixty-eight children with severe MAS who were treated in our hospital from March 2017 to March 2019 were enrolled. The patients were randomly divided into the control group (34 cases) for anti-infection and ventilator-assisted treatment. PS treatment was used on the basis of the control group and the NAC nebulizing solution was inhaled. The mean airway pressure (MAP), resistance (Raw), compliance (Cydn), lung function index, serum interleukin-8 (IL-8), IL-10, and platelet-derived growth factor (PDGF) were observed. Vascular endothelial growth factor (VEGF) levels were recorded, and the hospital stay, oxygen exposure time, upper ventilator time, and complications were recorded. RESULTS:During the 24 h observation group, Raw and MAP were lower than 0 h, the control group was lower, Cydn was higher than 0 h, and the control group was increased. In 72 h, the Raw and MAP of the observation group were lower than that of the control group, the Cydn was lower than that of the control group, and the Cydn was higher than the control group. The difference was statistically significant (P＜0.05). PaCO2, PaO2, a/APO2 in the observation group were higher than those in the control group at 1 h, 12 h and 24 h after treatment. The OI was lower than the control group, the difference was statistically significant (P＜0.05). The serum IL-10 level in the observation group was higher than that in the control group at 24 hours after treatment, and the serum IL-8 level was lower than that in the control group (P＜0.05). The serum of the observation group was observed at 24 h and 72 h after treatment. The levels of PDGF and VEGF were lower than those of the control group, and the difference was statistically significant (P＜0.05).CONCLUSION:Acetylcysteine combined with pulmonary surfactant can significantly improve the clinical efficacy of children with meconium aspiration syndrome. It may inhibit lung inflammation by regulating the expression of VEGF and PDGF, thus improving lung function in children.

Key words: fetal fecal inhalation syndrome, pulmonary surfactant, acetylcysteine, oxygenation, inflammatory factors

CLC Number:

R722.1

JIANG Li, LI Yuning, PANG Lihong, ZHANG Xingdao, WANG Fang. N-acetylcysteine combined with pulmonary surfactant alleviates neonatal severe fetus seizure syndrome through regulating fetal inflammatory factors and oxygenation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 81-86.

References

［1］陈文超, 程红斌. 新生儿重症胎粪吸入综合征呼吸机联合肺表面活性物质治疗的疗效及预后分析［J］. 湖南师范大学学报(医学版), 2018, 62(3): 159-161.
［2］Elsharnouby NM, Eid HE, Abou Elezz NF, et al. Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: a study of different doses ［J］. J Critical Care, 2014, 29(1): 182-186.
［3］黄泰, 吴明赴, 符明凤, 等. 某院2004～2011年新生患儿转运和非转运住院死亡率分析［J］. 中国中西医结合儿科学, 2015, 7(5): 462-464.
［4］Shohrati M, Karimzadeh I, Saburi A, et al. The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: a literature review ［J］. Inhala Toxicol, 2014, 26(9): 507-513.
［5］宋桂玲. 肺表面活性物质对新生儿重症胎粪吸入综合征炎症反应及氧合功能的影响［J］. 临床和实验医学杂志, 2016, 15(17): 1727-1730.
［6］Müller B, Oske M, Hochscheid R, et al. Effect of N‐acetylcysteine treatment on NO2‐impaired type II pneumocyte surfactant metabolism ［J］. Euro J Clin Invest, 2015, 31(2): 179-188.
［7］Manniello MD, Del GP, Aquino RP, et al. Clarithromycin and N-Acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility ［J］. Int J Pharmaceut, 2017, 533(2): 2661-2665.
［8］霍梦月, 梅花, 张钰恒, 等. 肺表面活性物质治疗胎粪吸入综合征临床疗效的Meta分析［J］. 中国小儿急救医学, 2018, 25(7): 541-545.
［9］Sponseller JK, Griffiths JK, Tzipori S. The evolution of respiratory cryptosporidiosis: evidence for transmission by inhalation ［J］. Clin Microbiol Rev, 2014, 27(3): 575-586.
［10］郑玉琼, 申川桥, 黄茂. 肺表面活性物质联合沐舒坦在新生儿胎粪吸入综合征中的应用［J］. 广西医科大学学报, 2018, 35(10): 118-121.
［11］Chris C, Macnutt MJ, Zhihong Z, et al. Anti-oxidant N-acetylcysteine diminishes diesel exhaust-induced increased airway responsiveness in person with airway hyper-reactivity ［J］. Toxicol Sci, 2014, 139(2): 479-487.
［12］黄静, 林新祝, 郑直. 高频振荡通气联合肺表面活性物质治疗新生儿重型胎粪吸入综合征并发肺出血的临床研究［J］. 中国当代儿科杂志, 2016, 18(11): 1075-1079.
［13］Sun Y, Qiu X, Wu G, et al. The effects of porcine pulmonary surfactant on smoke inhalation injury ［J］. J Surgical Res, 2015, 198(1): 200-207.
［14］王娴, 姚宝珍. 重复使用肺表面活性物质治疗新生儿重症胎粪吸入综合征的临床研究［J］. 检验医学与临床, 2016, 13(4): 475-476.
［15］郝莉霞, 王飞, 马晓鹏. 肺表面活性物质两种气管内给药方式治疗重症胎粪吸入综合征疗效比较［J］. 儿科药学杂志, 2016, 7(4): 19-22.
［16］Suzuki T, Trapnell BC. Pulmonary alveolar proteinosis syndrome ［J］. Clin Chest Med, 2016, 37(3): 431-440.
［17］王丽, 王秋月. 布地奈德联合肺表面活性物质气管内滴入治疗胎粪吸入综合征的临床效果［J］. 中国医药导报, 2018, 481(23): 73-76.
［18］Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury ［J］. Am J Res Critical Care Med, 2002, 166(10): 1332-1336.

[1]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
[4]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[5]	HU Linlin, XU Silu, LI Weilan, HE Jie, ZHANG Jinglu, SHAO Hua. Effects of extracorporeal membrane oxygenation on pharmacokinetics and pharmacodynamics of daptomycin in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 39-46.
[6]	YANG Huifang, LUO Ying, ZHAO Li. Effects of dexmedetomidine on renal function and serum inflammatory factors in sepsis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 857-861.
[7]	ZHAO Wei, WU Youyang, LIN Cong, HUANG Shiwei, CHEN Hao, JIANG Wenbing. Effects of pterostilbene on myocardial function, myocardial fibrosis and inflammatory response in rats with acute myocardial infarction and on Notch1/eIF3a signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 498-504.
[8]	PI Zhibing, YANG Xuezhi, PENG Yu, ZHANG Junkai, ZHANG Lei, LIN Hai. Effects of low-dose baclofen adjuvant therapy on patients with trigeminal neuralgia and its effects on inflammatory factors and oxidative stress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 317-322.
[9]	WU Jiayuan, ZHENG Li, MO Juanfen, GUO Li, CAO Chenxi, BAO Yi. Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 989-996.
[10]	LI Zhengzheng, CHEN Jin, PAN Zhenzhen, PAN Sipei, ZHANG Nan. Inhibitory effect and mechanism of quercetin on secondary endotoxemia in rats with Neisseria infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 658-664.
[11]	SHI Tieying, ZHOU Qihao, FENG Li, ZHOU Dongming, HOU Zhenhai. Effects of vertebroplasty combined with Bushen Buxue Recipe on postoperative inflammatory factors and re-fracture in patients with vertebral fracture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 212-217.
[12]	BAI Xuemin, ZOU Likao, JIN Zhenmu, JIANG Lijia. Effects of N-acetylcysteine on regulation of EGFR/MAPK signaling pathway in airway mucus hypersecretion in chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1120-1127.
[13]	XIE Fangying, CHEN Zheli, GAO Yuelan. Effects of Yiqi Yangyinshengji recipe on rats with recurrent oral ulcer and its effect on mucosal inflammatory factors and immune function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 20-26.
[14]	LI Jinyu, HUANG Danmei, ZHANG Yanmei, SHI Ganggang, WANG Bin. Macrophage migration inhibitory factor protects H9c2 cardiac myocytes against hypoxia/reoxygenation injury through regulation of autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 531-535.
[15]	ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.